{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '2', 'BACKGROUND', '2.1', 'Hypothesis', 'Currently there are two competing standards of care for first-line treatment of patients with', 'metastatic hormone sensitive prostate cancer (mHSPC), with docetaxel plus ADT and', 'abiraterone plus ADT both demonstrating improved disease control over ADT alone. No direct', 'comparisons have been done between these therapies, so the optimal treatment for these', 'patients is currently not clear.', 'The first studies published to demonstrate improved overall survival over monotherapy of', 'androgen deprivation therapy (ADT) alone were the CHAARTED and STAMPEDE\u00b2 (arms', 'A, B, C and E) prospective clinical trials. In the CHAARTED study, 790 patients were', 'randomized to ADT alone versus ADT plus 6 cycles of docetaxel. The median overall survival', '(OS) with the addition of docetaxel was significantly longer 57.6 months VS. 44.0 months', '(hazard ratio (HR) 0.61; 95% confidence interval {CI}, 0.47-0.80; P<0.001). These finding', 'were verified in the STAMPEDE trial where six cycles of docetaxel plus ADT also improved', 'clinical outcomes over ADT alone. The two docetaxel arms resulted in significant', 'improvement to os compared to the two ADT alone arms with hazard ratios of 0.78 (95% CI,', '0.66-093; p=0.006) and 0.82 (95% CI, 0.69-0.97; p=0.022) respectively.', 'Two studies have shown superior outcomes with the addition of abiraterone to ADT in', 'mHSPC, the LATITUDE\u00b3 and STAMPEDE4 (arms A and G) clinical trials. The LATITUDE', 'trial randomized 1199 patients and the STAMPEDE randomized 1917 patients to ADT versus', 'ADT plus abiraterone. The combination improved the median os in the LATITUDE trial (not', 'reached VS. 34.7 months; HR 0.62; 95% CI, 0.51-0.76; P<0.001) and improved 3 year', 'survival in the STAMPEDE trial at 83% VS 76% (HR 0.63; 95% CI 1.0.52-0.76; P<0.001).', 'These two approaches of combination therapy have not been directly compared so no high-', 'level evidence is available to make optimal treatment choices based on clinical outcomes.', 'Treatment decision is instead based on other clinical factors such as drug availability, fitness', 'for chemotherapy, toxicity or cost.', '5', 'There is likely a difference in these treatments regarding toxicities and cost. For instance,', 'docetaxel is known to cause alopecia, febrile neutropenia fatigue and neuropathy. Abiraterone', 'is known to cause fatigue, drug induced hepatitis and hypertension. There are differences in', 'the treatment duration as well with docetaxel given for 6 cycles (approximately 4 months)', 'whereas abiraterone is given until disease progression which may result in differences in', 'quality of life and does result in difference in financial expense. 6 The patient reported outcomes', 'in the LATITUDE study favored the combination group7. The reported quality of life was', 'initially worse with docetaxel than ADT alone at three months, but better than ADT alone at', '12 months in the CHAARTED study.8', 'Finally, there might be molecularly identified subgroups that will preferentially respond to a', 'hormonal based treatment (i.e. ADT + abiraterone) or a chemotherapy based treatment (i.e.', 'ADT + docetaxel). For instance, previous studies have demonstrated some subgroups of', 'patients in the castration-resistant setting that are more sensitive to docetaxel over', 'abiraterone.9-11', 'We hypothesize that treatment efficacy will be similar across the entire population studied in', 'this clinical trial between ADT + docetaxel versus ADT + abiraterone. However, we', 'Page 12 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'hypothesize that quality of life will be superior throughout the study for the abiraterone treated', 'patients. Doing this clinical trial directly comparing these two treatment options will also allow', 'for exploratory analysis of biomarkers of treatment response between hormonal versus', 'chemotherapy treatment in this population of patients which may identify additional factors', 'that may be important in the treatment selection between docetaxel and abiraterone for this', 'patient population.', '3', 'DRUG INFORMATION', '3.1', 'Androgen Deprivation Therapy', \"All subjects must receive ADT of Investigator's choice (LHRH agonist or antagonist, or\", 'orchiectomy) per FDA approved dosing regulations as standard therapy for the duration of the', 'clinical trial. Patients should maintain a castrate level testosterone concentration (i.e. total', 'testosterone VI 50 ng/dL) as validation of therapeutic efficacy for the chosen ADT therapy.', '3.2', 'Docetaxel (Taxotere)', 'Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells', 'that is essential for mitotic and interphase cellular functions.', 'Refer to Sanofi Package Insert for detail regarding clinical administration of TAXOTERE. The', 'following information is taken from the Package Insert', '3.2.1', 'Pharmacology', 'Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules', 'while simultaneously inhibiting their disassembly. This leads to the production of microtubule', 'bundles without normal function and to the stabilization of microtubules, which results in the', 'inhibition of mitosis in cells.', 'The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration', 'of 20 mg/m2 to 115 mg/m2 in phase 1 studies. The area under the curve (AUC) was dose', 'proportional following doses of 70 mg/m2 to 115 mg/m2 with infusion times of 1 to 2 hours.', \"Docetaxel's pharmacokinetic profile is consistent with a three-compartment pharmacokinetic\", 'model, with half-lives for the a., \u00df, and Y phases of 4 min, 36 min, and 11.1 hr, respectively.', 'Mean total body clearance was 21 L/h/m2.', 'Distribution: The initial rapid decline represents distribution to the peripheral compartments', 'and the late (terminal) phase is due, in part, to a relatively slow efflux of docetaxel from the', 'peripheral compartment. Mean steady state volume of distribution was 113 L. In vitro studies', 'showed that docetaxel is about 94% protein bound, mainly to x-1-acid glycoprotein, albumin,', 'and lipoproteins. In three cancer patients, the in vitro binding to plasma proteins was found to', 'be approximately 97%. Dexamethasone does not affect the protein binding of docetaxel.', 'Metabolism: In vitro drug interaction studies revealed that docetaxel is metabolized by the', 'CYP3A4 isoenzyme, and its metabolism may be modified by the concomitant administration', 'of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4.', 'Elimination: A study of 14C-docetaxel was conducted in three cancer patients. Docetaxel was', 'eliminated in both the urine and feces following oxidative metabolism of the tert-butyl ester', 'Page 13 of 52']\n\n###\n\n", "completion": "END"}